Management Board of Directors and Senior Management

Dr Nicolas Huber

Chief Executive Officer

Dr Huber completed his PhD in Space Science in reconfigurable hardware for space weather exploration on the International Space Station. After working in the aerospace sector he transitioned to the biomedical sciences, and over the past 8 years has been focused on medical device research and commercialization, where he developed and led a new portfolio of medical devices in radiation therapy for cancer treatment, building and leading a product development team and a new business line within an established multinational.

Dr Huber for the past few years has also been mentoring Healthcare startups through established accelerators (Wayra, RG, TechStars), specializing in business model development, market access and positioning

Mr Mahesh Shah

Non-Executive Director

An entrepreneur with over thirty years’ experience in the industry. Mahesh was a founding director of Nucare plc, a company operating in the Pharmaceutical Sector. He became the Sales & Marketing Director in 2000 and was CEO from 2002-2009, growing the company organically as well as by joint ventures and acquisitions with operations in the UK as well as overseas. He managed 250 employees and a wide shareholder base with over 700 shareholders. In November 2007 he led a successful trade sale for the company realising an enterprise value of approximately £70 million.

Mahesh has a number of investments in other business sectors and has held board positions with a number of start-up companies, playing a significant role in strategy and commercial agreements.

Dr Alex Betz

Non-Executive Director

Dr Betz completed a PhD on the hypermutation of immunoglobulin genes at the MRC Laboratory of Molecular Biology, Cambridge UK. After 3.5 years working as a post-doc at the Howard Hughes Medical Institute, Johns Hopkins University, Baltimore USA, he was recruited back to the MRC Laboratory of Molecular Biology. His initial research interest was the regulation of lymphocyte migration by chemokines. In 2004 he published his group’s breakthrough discovery that regulatory T cells maintain maternal tolerance to the fetus.  He retired from academic research in 2015 and now focuses on helping commercial projects.

Mr Peter Klimt

Non-Executive Director

Mr Klimt is an experienced entrepreneur with extensive practical expertise in international business including investment, and mergers and acquisitions

He has professional qualifications in law and practised as a corporate lawyer. He is currently CEO of Welbeck Investment Management Limited.